Sunday 18 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.25 | 2.18 | 2.06 | 3.28 | |
Current Ratio |
3.83 | 2.59 | 2.40 | 3.81 | |
Net Debt/EBITDA |
5.93 | 5.84 | 6.65 | 6.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.55 | 0.49 | 4.42 | |
Capex/Depreciation |
(0.01) | 0.00 | (0.04) | 0.01 | |
Interest Coverage |
(489.47) | (257.96) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.51) | (0.26) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.33) | (0.51) | (0.26) | (0.28) | |
Cash per Share |
2.36 | 2.60 | 2.28 | 2.28 | |
Shareholders Equity per Share |
2.07 | 1.90 | 1.58 | 1.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.07 | 1.90 | 1.58 | 1.98 | |
Free Cash Flow |
(5.96) | (8.03) | (6.25) | (7.60) | |
Working Capital |
37.16 | 30.02 | 37.06 | 52.62 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | 0.00 | |
Net Current Asset Value |
37.16 | 30.02 | 36.84 | 52.56 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.75 | 0.72 | 1.27 | 1.50 | |
Average Assets |
44.59 | 40.40 | 46.18 | 51.01 | |
Average Common Equity |
32.67 | 18.81 | 24.49 | 34.85 |
Columns are period end dates